Contineum, J&J's drug fails in mid-stage depression trial

Contineum Therapeutics and Johnson & Johnson’s oral M1 receptor inhibitor has missed its second mid-stage study in a year, this time in major depressive disorder. The drug, called PIPE-307 or JNJ-5120, failed to show statistically ...